<!DOCTYPE html>
<!--[if lt IE 9]><html class="no-js lt-ie9" lang="en" dir="ltr"><![endif]--><!--[if gt IE 8]><!-->
<html class="no-js" lang="fr" dir="ltr">
<!--<![endif]-->
<head>
    <meta charset="utf-8" />
    <!-- Web Experience Toolkit (WET) / Boîte à outils de l'expérience Web (BOEW)
        wet-boew.github.io/wet-boew/License-en.html / wet-boew.github.io/wet-boew/Licence-fr.html -->
    <title>Guide API - Rapports sommaires</title>
    <meta content="width=device-width,initial-scale=1" name="viewport">
    <!-- Meta data -->
    <meta name="dcterms.language" title="ISO639-2" content="fra" />
    <meta name="dcterms.title" content="Guide API - Rapports sommaires" />
    <meta name="description" content="Guide API - Rapports sommaires." />
    <meta name="dcterms.subject" title="scheme" content="" />
    <meta name="dcterms.creator" content="Gouvernement du Canada, Santé Canada et l'Agence de la santé publique du Canada" />
    <meta name="dcterms.contributor" content="" />
    <meta name="dcterms.type" title="gctype" content="" />
    <meta name="dcterms.audience" title="gcaudience" content="" />
    <meta name="dcterms.issued" title="W3CDTF" content="2017-11-30" />
    <meta name="dcterms.modified" title="W3CDTF" content="20176-11-30" />
    <meta name="review_date" content="" />
    <meta name="meta_date" content="" />

    <!-- Load closure template scripts -->
    <script type="text/javascript" src="https://ssl-templates.services.gc.ca/app/cls/wet/gcweb/v4_0_21/js/compiled/soyutils.js"></script>
    <script type="text/javascript" src="https://ssl-templates.services.gc.ca/app/cls/wet/gcweb/v4_0_21/js/compiled/wet-fr.js"></script>
    <script type="text/javascript" src="https://ssl-templates.services.gc.ca/app/cls/wet/gcweb/v4_0_21/js/compiled/plugins-fr.js"></script>
    <!-- Load closure template scripts -->
    <noscript>
        <link rel="import" href="./StaticFallbackFiles/gcweb/refTop.html">
    </noscript>
    <!-- Write closure template -->
    <script type="text/javascript">
            document.write(wet.builder.refTop({
                cdnEnv: "prod"
            }));
    </script>

    <!-- Google Tag Manager DO NOT REMOVE OR MODIFY - NE PAS SUPPRIMER OU MODIFIER -->
    <script>dataLayer1 = [];</script>
    <!-- End Google Tag Manager -->
</head>

<body vocab="http://schema.org/" typeof="WebPage">
    <!-- Google Tag Manager DO NOT REMOVE OR MODIFY - NE PAS SUPPRIMER OU MODIFIER -->
    <noscript>
        <iframe title="Google Tag Manager" src="//www.googletagmanager.com/ns.html?id=GTM-TLGQ9K" height="0" width="0"
                style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement

(s),dl=l!='dataLayer1'?'&l='+l:'';j.async=true;j.src='//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})

(window,document,'script','dataLayer1','GTM-TLGQ9K');
    </script>
    <!-- End Google Tag Manager -->
    <div id="def-top">
        <!-- top-en.html-Start-->
        <link rel="import" href="./StaticFallbackFiles/gcweb/top-fr.html">
        <!-- top-en.html-End-->
    </div>
    <!-- Write closure template -->
    <script type="text/javascript">
	var defTop = document.getElementById("def-top");
	var jsonbread = [];

	//console.log(jsonbread);
	defTop.outerHTML = wet.builder.top({
	    cdnEnv: "prod",
	    search: true,
		lngLinks: [{
			lang: "fr",
			href: "noc-documentation-en.html",
			text: "English",
		}],
		showPreContent: true,
		breadcrumbs:jsonbread,
	});
    </script>
    <div class="container">
        <main role="main" property="mainContentOfPage" class="container">
            <div class="wb-frmvld">
                <section>
                    <h1 id="wb-cont">Guide API - Rapports sommaires</h1>                    
                    <section>
                        <h2 id="a">Table des matières</h2>
                        <ul>
                            <li><a href="#a1">Introduction</a></li>
                            <li>
                                <a href="#a2">Sommaire des motifs de décision</a>
                                <ul>
                                    <li><a href="#a2.1">Paramètres</a></li>
                                    <li><a href="#a2.2">Format du résultat</a></li>
                                    <li><a href="#a2.3">Exemple de résultat</a></li>
                                    <li><a href="#a2.4">Exemple de jQuery</a></li>
                                </ul>
                            </li>
                            <li>
                                <a href="#a3">Sommaire des décisions réglementaires</a>
                                <ul>
                                    <li><a href="#a3.1">Paramètres</a></li>
                                    <li><a href="#a3.2">Format du résultat</a></li>
                                    <li><a href="#a3.3">Exemple de résultat</a></li>
                                    <li><a href="#a3.4">Exemple de jQuery</a></li>
                                </ul>
                            </li>
                            <li>
                                <a href="#a4">Examen de l'innocuité</a>
                                <ul>
                                    <li><a href="#a4.1">Paramètres</a></li>
                                    <li><a href="#a4.2">Format du résultat</a></li>
                                    <li><a href="#a4.3">Exemple de résultat</a></li>
                                    <li><a href="#a4.4">Exemple de jQuery</a></li>
                                </ul>
                            </li>
                        </ul>
                    </section>                    
                    <section>
                        <h2 id="a1">Introduction</h2>
                        <p>The Drug and Health Product Register web site brings together Information on product licences, drug and health product inspections, buying and using products safely, and side effects, recalls and complaints.</p>
                        <p>Cette interface de programmation d'applications (API) permet aux concepteurs d'accéder à ces renseignements en format JSON, XML et CSV afin de les utiliser dans leurs propres applications.</p>
                        <p>L'adresse URI de base sur les rapports sommaires est &nbsp;<a href="https://imsd.hres.ca/regcontent/api/">https://imsd.hres.ca/regcontent/api/</a>. Toute requête est effectuée par l'entremise de cette adresse URI.</p>                        
                    </section>
                    <!--Summary Basis of Decision-section-start-->
                    <section>
                        <h2 id="a2">Sommaire des motifs de décision</h2>
                        <p>Les documents de sommaire des motifs de décision expliquent pourquoi Santé Canada a autorisé la vente de certains médicaments et instruments médicaux au Canada. Les aspects pris en compte sont la réglementation, l'innocuité, 
                            l'efficacité et la qualité (sur le plan de la chimie et de la fabrication).</p>
                        <!--h3-section-start-->
                        <section>
                            <h3 id="a2.1">Paramètres</h3>
                            <p>Il y a trois paramètres dans la requête : id, lang et type.</p>
                            <table>
                                <caption>
                                    Paramètres pour la requête
                                </caption>
                                <tr>
                                    <th scope="col">Paramètre</th>
                                    <th scope="col">Définition</th>
                                    <th scope="col">Valeur</th>
                                    <th scope="col">Requis?</th>
                                    <th scope="col">Note</th>
                                </tr>
                                <tr>
                                    <td><span class="nowrap">regcontent/api/basisdecision?id=SBD00001</span></td>
                                    <td>Affiche le sommaire des motifs de décision selon le format du rapport spécifié dans la requête.</td>
                                    <td>
                                        <ul class="list-unstyled mrgn-lft-0 wrap">
                                            #####&nbsp;- format du rapport
                                        </ul>
                                    </td>
                                    <td><strong>Oui</strong></td>
                                    <td></td>
                                </tr>
                                <tr>
                                    <td><span class="nowrap">regcontent/api/basisdecision/?lang=fr</span></td>
                                    <td>Modifie la langue du résultat affiché.</td>
                                    <td>
                                        <ul class="list-unstyled mrgn-lft-0 nowrap">
                                            <li><code>en</code>&nbsp;- Anglais</li>
                                            <li><code>fr</code>&nbsp;- Fran&ccedil;ais</li>
                                        </ul>
                                    </td>
                                    <td><strong>Non</strong>, mais l'anglais est la langue par défaut si elle n'est pas spécifiée</td>
                                    <td>Détermine si le résultat est affiché en anglais ou en français.</td>
                                </tr>
                                <tr>
                                    <td><span class="nowrap">regcontent/api/basisdecision/?type=json</span></td>
                                    <td>Modifie le format du résultat.</td>
                                    <td>
                                        <ul class="list-unstyled mrgn-lft-0 nowrap">
                                            <li><code>json</code>&nbsp;- JSON</li>
                                            <li><code>xml</code>&nbsp;- XML</li>
                                            <li><code>csv</code>&nbsp;- CSV</li>
                                        </ul>
                                    </td>
                                    <td><strong>Non</strong>, mais JSON est le format par défaut s'il n'est pas spécifié.</td>
                                    <td>Détermine si le résultat est en format JSON, XML ou CSV.</td>
                                </tr>
                            </table>
                            <p> La liste des sommaires des motifs de décision peut être accédée aux adresses URI suivantes&nbsp;:</p>
                            <ul>
                                <li><a href="https://imsd.hres.ca/regcontent/api/basisdecision/?lang=en&type=json">https://imsd.hres.ca/regcontent/api/basisdecision/?lang=en&type=json</a></li>
                                <li><a href="https://imsd.hres.ca/regcontent/api/basisdecision/?lang=fr&type=json">https://imsd.hres.ca/regcontent/api/basisdecision/?lang=fr&type=json</a></li>
                            </ul>
                        </section>                        
                        <section>
                            <h3 id="a2.2">Format du résultat</h3>
                            <p>Le <strong>résultat</strong> contient un ou plusieurs objets.</p>
                            <p>Chaque objet&nbsp;<strong>sommaire des motifs de décision</strong>&nbsp;contient les valeurs suivantes&nbsp;:</p>
                            <table>
                                <caption>
                                    Valeurs de l'objet sommaire des motifs de décision
                                </caption>
                                <tr>
                                    <th scope="col">Code</th>
                                    <th scope="col">Valeur</th>
                                </tr>
                                <tr>
                                    <td><strong>template</strong></td>
                                    <td>There are two different formats for the SBDs.  This variable defines which template is used.  Possible values are1 or 2.</td>
                                </tr>
                                <tr>
                                    <td><strong>control_number</strong></td>
                                    <td>The control number (for the new drug submission).</td>
                                </tr>
                                <tr>
                                    <td><strong>date_issued</strong></td>
                                    <td>The date the SBD was issued.</td>
                                </tr>
                                <tr>
                                    <td><strong>link_id</strong></td>
                                    <td>This variable is used to link all of the SBD data together.</td>
                                </tr>
                                <tr>
                                    <td><strong>brand_name</strong></td>
                                    <td>The brand name.</td>
                                </tr>
                                <tr>
                                    <td><strong>manufacturer</strong></td>
                                    <td>The manufacturer.</td>
                                </tr>
                                <tr>
                                    <td><strong>med_ingredient</strong></td>
                                    <td>The medicinal ingredient.</td>
                                </tr>
                                <tr>
                                    <td><strong>bd_din_list</strong></td>
                                    <td>Reference number that links the SBD information together.</td>
                                </tr>
                                <tr>
                                    <td><strong>sub_type_number</strong></td>
                                    <td>The submission type and its number.</td>
                                </tr>
                                <tr>
                                    <td><strong>date_submission</strong></td>
                                    <td>The date of the submission.</td>
                                </tr>
                                <tr>
                                    <td><strong>date_authorization</strong></td>
                                    <td>The date it was authorized.</td>
                                </tr>
                                <tr>
                                    <td><strong>notice_decision</strong></td>
                                    <td>The notice of decision text.</td>
                                </tr>
                                <tr>
                                    <td><strong>sci_reg_decision</strong></td>
                                    <td>The scientific and regulatory basis for decision text.</td>
                                </tr>
                                <tr>
                                    <td><strong>quality_basis</strong></td>
                                    <td>The quality basis for decision text.</td>
                                </tr>
                                <tr>
                                    <td><strong>non_clin_basis</strong></td>
                                    <td>The Non-Clinical basis for decision text.</td>
                                </tr>
                                <tr>
                                    <td><strong>non_clin_basis2</strong></td>
                                    <td>The Non-Clinical basis for decision text continued.  This field is concatenated with NonclinBasis if the character limit for that field is exceeded.</td>
                                </tr>
                                <tr>
                                    <td><strong>clin_basis</strong></td>
                                    <td>The Clinical Basis for decision.</td>
                                </tr>
                                <tr>
                                    <td><strong>clin_basis2</strong></td>
                                    <td>The Clinical Basis for decision continued.  This field is concatenated with ClinBasis if the character limit for that field is exceeded.</td>
                                </tr>
                                <tr>
                                    <td><strong>clin_basis3</strong></td>
                                    <td>The clinical basis for decision continued.  This field is concatenated with ClinBasis2 if the character limit for that field is exceeded.</td>
                                </tr>
                                <tr>
                                    <td><strong>benefit_risk</strong></td>
                                    <td>The Benefit/Risk Assessment and Recommendation text.</td>
                                </tr>
                                <!--
                                <tr>
                                    <td><strong>radioisotope</strong></td>
                                    <td>The radioisotope type.</td>
                                </tr>
                                -->
                                <tr>
                                    <td><strong>summary</strong></td>
                                    <td>The “Summary Basis of Decision” introductory text.</td>
                                </tr>
                                <tr>
                                    <td><strong>what_approved</strong></td>
                                    <td>The “What was approved?” text.</td>
                                </tr>
                                <tr>
                                    <td><strong>why_approved</strong></td>
                                    <td>The reason why the product was approved.</td>
                                </tr>
                                <tr>
                                    <td><strong>steps_approval</strong></td>
                                    <td>The steps for approval.</td>
                                </tr>
                                <tr>
                                    <td><strong>assess_basis</strong></td>
                                    <td>The concluding text in section 3 "What led to the approval".</td>
                                </tr>
                                <tr>
                                    <td><strong>followup_measures</strong></td>
                                    <td>The follow-up measures that the company will take.</td>
                                </tr>
                                <tr>
                                    <td><strong>post_auth</strong></td>
                                    <td>The post-authorization activity that has taken place for the drug.</td>
                                </tr>
                                <tr>
                                    <td><strong>other_info</strong></td>
                                    <td>The other information available about drugs.</td>
                                </tr>
                                <tr>
                                    <td><strong>a_sci_reg_decision</strong></td>
                                    <td>The scientific rationale for Health Canada’s decision introductory text.</td>
                                </tr>
                                <tr>
                                    <td><strong>science_rationale</strong></td>
                                    <td>The scientific rationale for Health Canada’s decision.</td>
                                </tr>
                                <tr>
                                    <td><strong>a_clin_basis</strong></td>
                                    <td>The Clinical Basis for Decision.</td>
                                </tr>
                                <tr>
                                    <td><strong>a_clin_basis2</strong></td>
                                    <td>The Clinical Basis for Decision continued.  This field is concatenated with AClinBasis if the character limit for that field is exceeded.</td>
                                </tr>
                                <tr>
                                    <td><strong>a_non_clin_basis</strong></td>
                                    <td>The Non-Clinical Basis for Decision.</td>
                                </tr>
                                <tr>
                                    <td><strong>a_non_clin_basis2</strong></td>
                                    <td>The Non-Clinical Basis for Decision continued.  This field is concatenated with ANonClinBasis if the character limit for that field is exceeded.</td>
                                </tr>
                                <tr>
                                    <td><strong>b_quality_basis</strong></td>
                                    <td>The Quality Basis for Decision.</td>
                                </tr>
                                <tr>
                                    <td><strong>din</strong></td>
                                    <td>The Drug Identification number(s).</td>
                                </tr>
                                <tr>
                                    <td><strong>licence_number</strong></td>
                                    <td>The product licence number.</td>
                                </tr>
                                <tr>
                                    <td><strong>is_md</strong></td>
                                    <td>The product is_md.</td>
                                </tr>
                                <tr>
                                    <td><strong>din_list</strong></td>
                                    <td>The list of Drug Identification number(s).</td>
                                </tr>
                                <tr>
                                    <td><strong>post_activity_list</strong></td>
                                    <td>The product post activity list</td>
                                </tr>
                                <tr>
                                    <td><strong>milestone_list</strong></td>
                                    <td>The product milestone list.</td>
                                </tr>
                                <tr>
                                    <td><strong>tombstone_list</strong></td>
                                    <td>The product tombstone list.</td>
                                </tr>
                            </table>
                        </section>
                        <section>
                             <h3 id="a2.3">Exemple de résultat</h3>
                             <pre class="prettify prettyprint linenums">{"Template":1,"ControlNum":"120192","DateIssued":"2009-11-26","LinkId":"SBD00001","Brandname":"ABILIFY","Manufacturer":"Bristol-Myers Squibb Canada","MedIngredient":"Aripiprazole","NonpropName":"Aripiprazole","Strength":"2 <abbr title=\"milligrams\">mg</abbr>, 5 <abbr title=\"milligrams\">mg</abbr>, 10 <abbr title=\"milligrams\">mg</abbr>, 15 <abbr title=\"milligrams\">mg</abbr>, 20 <abbr title=\"milligrams\">mg</abbr>, and 30 <abbr title=\"milligrams\">mg</abbr>","Dosageform":"Tablet","RouteAdmin":"Oral","BdDinList":1,"TheraClass":"Antipsychotic","NonmedIngredient":"Cornstarch, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and coloring agents (2 mg: FD&C Blue No. 2 Aluminum Lake and iron oxide Yellow; 5 mg: FD&C Blue Number 2 Aluminum Lake; 10 mg and 30 mg: iron oxide red; 15 mg: iron oxide yellow).","SubTypeNum":"New Drug Submission, Control Number: 120192","DateSubmission":"2008-02-22","DateAuthorization":"2009-07-09","NoticeDecision":"<p>On July 9, 2009, Health Canada issued a Notice of Compliance to Bristol-Myers Squibb Canada for the drug product Abilify.</p> <p>Abilify contains the medicinal ingredient aripiprazole which is a novel, atypical antipsychotic drug.</p> <p>Abilify is indicated for:</p> <ul class=\"data-spacing-bottom\"> <li>Schizophrenia - Abilify is indicated for the treatment of schizophrenia and related psychotic disorders.</li> <li>Bipolar Disorder - Abilify is indicated for the acute treatment of manic or mixed episodes in Bipolar I Disorder. Abilify may be used as acute monotherapy or cotherapy with lithium or divalproex sodium when there is an insufficient acute response to these agents alone.</li> </ul> <p>Schizophrenia is a severe and chronic psychotic disorder with fluctuating disturbances in thinking, behaviour, and perception, with potential for significant impairment of occupational and social functioning. Bipolar I Disorder is a lifelong episodic illness characterized by manic, depressive or mixed (symptoms of manic and depressive) episodes followed by symptom-free periods. Bipolar disorder is associated with severe impairment of social, occupational, and cognitive functioning. The mechanism of action of aripiprazole is unknown. It has been proposed that the efficacy of aripiprazole may be mediated through a combination of partial agonist activity at the dopamine D2 and serotonin 5-HT1A receptors, and antagonist activity at the serotonin 5-HT2A receptors; but, the clinical relevance of these interactions has not been established.</p> <p>The market authorization was based on quality, non-clinical, and clinical information submitted. The efficacy of Abilify for the acute treatment of schizophrenia was evaluated in five short-term (4- and 6-week), placebo-controlled studies of acutely relapsed inpatients who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-III/IV) criteria for schizophrenia or schizoaffective disorder. In four of the five studies Abilify was superior to placebo for the primary efficacy endpoint. The short-term efficacy of the 10-<abbr>mg</abbr>, 15-<abbr>mg</abbr>, 20-<abbr>mg</abbr>, and 30-<abbr>mg</abbr> daily doses in schizophrenia was established in two studies for each dose. There was no evidence that the higher dose groups offered any advantage over the 10-<abbr>mg</abbr> dose group. Overall, in short-term studies, Abilify improved both positive and negative symptoms. In a longer-term study, time to relapse was evaluated in inpatients and outpatients meeting DSM-IV criteria for schizophrenia. In that study, Abilify was more effective than placebo in maintaining clinical improvement for up to 26 weeks.</p> <p>The efficacy of Abilify, used as monotherapy, for the acute treatment of Bipolar I Disorder was evaluated in four Phase III, 3-week, randomized, double-blind, placebo-controlled clinical studies of hospitalized patients who met the DSM-IV criteria for Bipolar I Disorder with manic or mixed episodes. Each study used flexible doses of Abilify (15 or 30 <abbr title=\"milligrams/day\">mg/day</abbr>, administered once daily (with a starting dose of 15 <abbr>mg/day</abbr> in two studies and 30 <abbr>mg/day</abbr> in two studies). The majority of patients that were treated with Abilify received 30 <abbr>mg/day</abbr>. In all four studies, Abilify was generally well-tolerated, and was superior to placebo in the reduction of manic symptoms. A separate Phase III, 6-week, randomized, double-blind, placebo-controlled study evaluated the efficacy of Abilify used as cotherapy with lithium or valproate in patients with manic or mixed episodes who had a partial response to lithium or valproate alone. This study demonstrated that Abilify (administered once daily as flexible doses of 15 or 30 <abbr>mg/day</abbr>, starting dose 15 <abbr>mg/day</abbr>) was superior to placebo, when each was administered concomitantly with lithium or valproate (at therapeutic serum levels) in the reduction of manic symptoms.</p> <p>Abilify (2 <abbr>mg</abbr>, 5 <abbr>mg</abbr>, 10 <abbr>mg</abbr>, 15 <abbr>mg</abbr>, 20 <abbr>mg</abbr>, and 30 <abbr>mg</abbr> aripiprazole) is presented as tablets. For patients with schizophrenia, the recommended starting and target dose for Abilify is 10 or 15 <abbr>mg/day</abbr> administered once daily. Dosage increases, if needed, should only be made after 2 weeks, the time needed to achieve steady-state. For patients with bipolar disorder, the recommended starting dose for Abilify as acute monotherapy or as cotherapy with lithium or valproate is 15 <abbr>mg</abbr> once daily. The dose can be increased to 30 <abbr>mg/day</abbr> based on clinical response. The maximum daily dose for both schizophrenia and bipolar patients should not exceed 30 <abbr>mg/day</abbr>, and for both indications, Abilify can be administered without regard to meals. Patients should be treated with the lowest effective dose that provides optimal clinical response and tolerability. Patients with schizophrenia should be periodically reassessed to determine the need for maintenance treatment. Dosing guidelines are available in the Product Monograph.</p> <p>Abilify is contraindicated for patients with a known hypersensitivity to this drug or the excipients of the product. Abilify should be administered under the conditions stated in the Product Monograph taking into consideration the potential risks associated with the administration of this drug product. Detailed conditions for the use of Abilify are described in the Product Monograph.</p> <p>Based on the Health Canada review of data on quality, safety, and efficacy, Health Canada considers that the benefit/risk profile of Abilify is favourable for the indications stated above.</p>","SciRegDecision":"The New Drug Submission (NDS) for Abilify was given a Notice of Non-Compliance (NON) on March 10, 2009 at the sponsor's request as they required additional time to evaluate and respond to clinical requirements in the Product Monograph and package labelling. The sponsor subsequently addressed all of the requirements in the NON and incorporated all revisions to the Product Monograph recommended by Health Canada. A Notice of Compliance (NOC) was issued for Abilify on July 9, 2009.","QualityBasis":"<p>The New Drug Submission (<abbr>NDS</abbr>) for Abilify was given a Notice of Non-Compliance (<abbr>NON</abbr>) on March 10, 2009 at the sponsor's request as they required additional time to evaluate and respond to clinical requirements in the Product Monograph and package labelling. The sponsor subsequently addressed all of the requirements in the <abbr>NON</abbr> and incorporated all revisions to the Product Monograph recommended by Health Canada. A Notice of Compliance (<abbr>NOC</abbr>) was issued for Abilify on July 9, 2009.</p> <h3 id=\"a31\">3.1 Quality Basis for Decision</h3> <h4 id=\"a311\">3.1.1 Drug Substance (Medicinal Ingredient)</h4> <h5><span class=\"strong\">General Information</span></h5> <p>Aripiprazole, the medicinal ingredient of Abilify, is an atypical antipsychotic drug. The mechanism of action of aripiprazole is unknown, however, its efficacy may be mediated through a combination of partial agonist activity at the dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at the serotonin 5-HT2A receptor. The clinical relevance of these interactions has yet to be established.</p> <h5><span class=\"strong\">Manufacturing Process and Process Controls</span></h5> <p>The drug substance is synthetically derived. The manufacturing process is considered to be adequately controlled within justified limits.</p> <h5><span class=\"strong\">Characterization</span></h5> <p>The structure of aripiprazole has been adequately elucidated and the representative spectra have been provided. Physical and chemical properties have been described and are found to be satisfactory.</p> <p>Impurities and degradation products arising from manufacturing and/or storage were reported and characterized. These products were found to be within International Conference on Harmonisation (<abbr>ICH</abbr>)-established limits and are therefore considered to be acceptable. Appropriate tests are adequately controlling the levels of product- and process-related impurities.</p> <h5><span class=\"strong\">Control of Drug Substance</span></h5> <p>The drug substance specifications and analytical methods used for quality control of aripiprazole are considered acceptable. Data from the batch analyses were reviewed and are within the proposed acceptance criteria.</p> <p>The levels of product- and process-related impurities were adequately monitored throughout the manufacturing process. Results from process validation reports and in-process controls indicate that the impurities of the drug substance are adequately under control. The level of impurities reported for the drug substance was found to be within the established limits.</p> }]}</pre>
                        </section>                            
                        <section>
                             <h3 id="a2.4">Exemple de jQuery</h3>
                             <p>Exemple d'une fonctionnalité qui recherche un sommaire des motifs de décision selon le format d'un rapport et la langue sélectionnée&nbsp;:</p>
                             <pre class="prettify prettyprint linenums">function getSummaryBasisOfDecision(id, lang) {
     var base = 'https://imsd.hres.ca';
     var uri = base + '/regcontent/api/basisdecision/?lang=' + lang + '&id=' + id;
     $.ajax({
             url:uri,
             type:'GET',
             Accept:&quot;application/json&quot;,
             dataType: 'json',
             success:function(data){
                          console.log(data.brand_name);
                          var frag = document.createDocumentFragment();
                          var h2 = document.createElement(&quot;h2&quot;);
                          var Brandname = document.createTextNode(data.brand_name);
                          var p = document.createElement(&quot;p&quot;);
                          var text = document.createTextNode(data.panels[0].text);
                          h2.appendChild(Brandname);
                          p.appendChild(text);
                          frag.appendChild(h2);
                          frag.appendChild(p);
                          $(&quot;#responses&quot;)[0].appendChild(frag);
             },
             error:function(error){
             },
      });
      return;
  };			</pre>   
                        </section>
                    </section>
                    <!--Summary Basis of Decision-section-end-->
                    <!--Regulatory Decision-section-start--> 
                    <section>
                        <h2 id="a3">Sommaire des décisions réglementaires</h2>
                        <p>Les sommaires des décisions réglementaires (SDR) expliquent les décisions de Santé Canada relativement à certains produits de santé pour lesquels une autorisation de mise en marché est demandée.</p>
                        <!--h3-section-start-->
                        <section>
                            <h3 id="a3.1">Paramètres</h3>
                            <p>Il y a trois paramètres dans la requête : id, lang et type.</p>
                            <table>
                                <caption>
                                    Paramètres pour la requête
                                </caption>
                                <tr>
                                    <th scope="col">Paramètre</th>
                                    <th scope="col">Définition</th>
                                    <th scope="col">Valeur</th>
                                    <th scope="col">Requis?</th>
                                    <th scope="col">Note</th>
                                </tr>
                                <tr>
                                    <td><span class="nowrap">regcontent/api/regulatorydecision?id=RDS00007</span></td>
                                    <td>Affiche le sommaire des décisions réglementaires selon le numéro d'identification spécifié dans la requête.</td>
                                    <td>
                                        <ul class="list-unstyled mrgn-lft-0 wrap">
                                            #####&nbsp;- numéro d'identification
                                        </ul>
                                    </td>
                                    <td><strong>Oui</strong></td>
                                    <td></td>
                                </tr>
                                <tr>
                                    <td><span class="nowrap">regcontent/api/regulatorydecision/?lang=fr</span></td>
                                    <td>Modifie la langue du résultat affiché.</td>
                                    <td>
                                        <ul class="list-unstyled mrgn-lft-0 nowrap">
                                            <li><code>en</code>&nbsp;- Anglais</li>
                                            <li><code>fr</code>&nbsp;- Fran&ccedil;ais</li>
                                        </ul>
                                    </td>
                                    <td><strong>Non</strong>, mais l'anglais est la langue par défaut si elle n'est pas spécifiée</td>
                                    <td>Détermine si le résultat est affiché en anglais ou en français.</td>
                                </tr>
                                <tr>
                                    <td><span class="nowrap">regcontent/api/regulatorydecision/?type=json</span></td>
                                    <td>Modifie le format du résultat.</td>
                                    <td>
                                        <ul class="list-unstyled mrgn-lft-0 nowrap">
                                            <li><code>json</code>&nbsp;- JSON</li>
                                            <li><code>xml</code>&nbsp;- XML</li>
                                            <li><code>csv</code>&nbsp;- CSV</li>
                                        </ul>
                                    </td>
                                    <td><strong>Non</strong>, mais JSON est le format par défaut s'il n'est pas spécifié.</td>
                                    <td>Détermine si le résultat est en format JSON, XML ou CSV.</td>
                                </tr>
                            </table>
                            <p> La liste des sommaires des décisions réglementaires peut être accédée aux adresses URI suivantes&nbsp;:</p>
                            <ul>
                                <li><a href="https://imsd.hres.ca/regcontent/api/regulatorydecision/?lang=en&type=json">https://imsd.hres.ca/regcontent/api/regulatorydecision/?lang=en&type=json</a></li>
                                <li><a href="https://imsd.hres.ca/regcontent/api/regulatorydecision/?lang=fr&type=json">https://imsd.hres.ca/regcontent/api/regulatorydecision/?lang=fr&type=json</a></li>
                            </ul>
                        </section> 
                        <section>
                            <h3 id="a3.2">Format du résultat</h3>
                            <p>Le <strong>résultat</strong> contient un ou plusieurs objets.</p>
                            <p>Chaque objet&nbsp;<strong>sommaire des décisions réglementaires</strong>&nbsp;contient les valeurs suivantes&nbsp;:</p>
                            <table>
                                <caption>
                                    Valeurs de l'objet sommaire des décisions réglementaires
                                </caption>
                                <tr>
                                    <th scope="col">Code</th>
                                    <th scope="col">Valeur</th>
                                </tr>
                                <tr>
                                    <td><strong>link_id</strong></td>
                                    <td>This variable is used to link all of the RDS data together.</td>
                                </tr>
                                <tr>
                                    <td><strong>drug_name</strong></td>
                                    <td>The brand name of the drug.</td>
                                </tr>
                                <tr>
                                    <td><strong>contact_name</strong></td>
                                    <td>The name of the Health Canada contact.</td>
                                </tr>
                                <tr>
                                    <td><strong>contact_url</strong></td>
                                    <td>The URL of the Health Canada contact.</td>
                                </tr>
                                <tr>
                                    <td><strong>medical_ingredient</strong></td>
                                    <td>The active ingredient.</td>
                                </tr>
                                <tr>
                                    <td><strong>therapeutic_area</strong></td>
                                    <td>The Therapeutic area.</td>
                                </tr>
                                <tr>
                                    <td><strong>purpose</strong></td>
                                    <td>The purpose of the submission.</td>
                                </tr>
                                <tr>
                                    <td><strong>reason_decision</strong></td>
                                    <td>Why was the decision issued.</td>
                                </tr>
                                <tr>
                                    <td><strong>decision</strong></td>
                                    <td>The Decision issued.</td>
                                </tr>
                                <tr>
                                    <td><strong>decision_descr</strong></td>
                                    <td>The explanatory text of the decision.</td>
                                </tr>

                                <tr>
                                    <td><strong>date_decision</strong></td>
                                    <td>The date of decision.</td>
                                </tr>
                                <tr>
                                    <td><strong>manufacturer</strong></td>
                                    <td>The manufacturer.</td>
                                </tr>
                                <tr>
                                    <td><strong>prescription_status</strong></td>
                                    <td>The prescription status.</td>
                                </tr>
                                <tr>
                                    <td><strong>type_submission</strong></td>
                                    <td>The type of submission.</td>
                                </tr>
                                <tr>
                                    <td><strong>date_filed</strong></td>
                                    <td>The date the submission was filed.</td>
                                </tr>
                                <tr>
                                    <td><strong>control_number</strong></td>
                                    <td>The control number for the submission.</td>
                                </tr>
                                <tr>
                                    <td><strong>created_date</strong></td>
                                    <td>The created date.</td>
                                </tr>
                                <!--
                                <tr>
                                    <td><strong>modified_date</strong></td>
                                    <td>The modified date. ????? yellow comment
                                    </td>
                                </tr>
                                <tr>
                                    <td><strong>footnotes</strong></td>
                                    <td>A reference number to the footnotes text.</td>
                                </tr>
                                                                    -->
                                                    <!--<tr>
                                    <td><strong>din</strong></td>
                                    <td>The product din.</td>
                                </tr>
                                <tr>
                                    <td><strong>is_md</strong></td>
                                    <td>The product is_md.</td>
                                </tr>
                                <tr>
                                    <td><strong>din_list</strong></td>
                                    <td>The product din_list.</td>
                                </tr>
                                <tr>
                                    <td><strong>bullet_list</strong></td>
                                    <td>The product bullet_list.</td>
                                </tr>-->
                            </table>
                        </section>
                        <section>
                             <h3 id="a3.3">Exemple de résultat</h3>
                             <pre class="prettify prettyprint linenums">{"LinkId":"RDS00007","Drugname":"AVASTIN","ContactName":"Office of Regulatory Affairs, Biologics and Genetic Therapies Directorate","ContactUrl":"http://www.hc-sc.gc.ca/contact/dhp-mps/hpfb-dgpsa/bgtd-pbtg-ora-bar-eng.php","MedicalIngredient":"Bevacizumab","TherapeuticArea":"Anti-neoplastic agent","Purpose":"This SNDS (control # 171255) was submitted to support the extension of the use of Avastin in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin for the treatment of patients with recurrent, platinum-resistantepithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC) who received no more than two prior chemotherapy regimens.","ReasonDecision":"<p>The pivotal trial submitted in support of this proposed indication demonstrated a statistically significant and clinically relevant improvement in progression free survival &nbsp;(PFS) of AVASTIN in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin over paclitaxel, topotecan or pegylated liposomal doxorubicin alone (absolute gain of 3.4 months in median PFS). These results were supported by an improvement in objective response rate (ORR) (partial responses) in the AVASTIN with chemotherapy treatment arm. The overall survival benefit was numerically in favour of the AVASTIN with chemotherapy treatment arm but the results were not statistically significant.</p><p>As expected, patients treated with AVASTIN resulted in increased safety findings compared to patients who received chemotherapy alone. However, the overall safety profile of AVASTIN in this population of patients appears to be consistent with the known safety profile of AVASTIN and is consistent with the experience of AVASTIN across indications. All safety concerns were adequately captured in the Product Monograph (PM).</p><p><strong>In view of the clinically meaningful PFS benefit associated with an ORR improvement in the context of this recurrent disease and a serious but identified safety profile, the overall risk benefit profile of AVASTIN appears to be favourable for the treatment of recurrent platinum-resistant ovarian cancer in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin in patients that have received no more than two prior chemotherapy regimens.</strong></p>","Decision":"Approved","DecisionDescr":"; issued Notice of Compliance in accordance with the &nbsp;<a href=\"http://laws-lois.justice.gc.ca/eng/regulations/C.R.C.%2C_c._870/?showtoc =&amp;instrumentnumber =C.R.C.,_c._870\" title=\"external link\"><em>Food and Drug Regulations</em></a>.","DateDecision":"2015-09-28","Manufacture":"Hoffmann-La Roche Limited","PrescriptionStatus":"AVASTIN is available by prescription only.","TypeSubmission":"SNDS","DateFiled":"2014-01-08","ControlNumber":171255,"CreatedDate":null,"ModifiedDate":"2015-10-14","Footnotes":0,"Din":"N/A","DinList":["N/A"],"BulletList":[]}</pre>
                        </section>                            <
                        <section>
                             <h3 id="a3.4">Exemple de jQuery</h3>
                             <p>Exemple d'une fonctionnalité qui recherche un sommaire des décisions réglementaires selon un numéro d'identification et la langue sélectionnée&nbsp;:</p>
                             <pre class="prettify prettyprint linenums">function getRegulatoryDecision(id, lang) {
      var base = 'https://imsd.hres.ca';
      var uri = base + '/regcontent/api/regulatorydecision/?lang=' + lang + '&id=' + id;
      $.ajax({
               url:uri,
               type:'GET',
               Accept:&quot;application/json&quot;,
               dataType: 'json',
               success:function(data){
                            console.log(data.drug_name);
                            var frag = document.createDocumentFragment();
                            var h2 = document.createElement(&quot;h2&quot;);
                            var Drugname = document.createTextNode(data.drug_name);
                            var p = document.createElement(&quot;p&quot;);
                            var text = document.createTextNode(data.panels[0].text);
                            h2.appendChild(Drugname);
                            p.appendChild(text);
                            frag.appendChild(h2);
                            frag.appendChild(p);
                            $(&quot;#responses&quot;)[0].appendChild(frag);
                },
                error:function(error){
                },
      });
      return;
  };			</pre>     
                        </section> 
                    </section>
                    <!--Regulatory Decision-section-end-->
                    <!--Summary Safety Review-section-start-->  
                    <section>
                        <h2 id="a4">Examen de l'innocuité</h2>
                        <p>Chaque produit de santé autorisé pour la vente au Canada a des conditions d'approbation et d'étiquetage qui reflètent la
                            compréhension des bénéfices et des effets nocifs du produit par Santé Canada au moment de l'approbation. Une fois sur le marché
                            canadien, Santé Canada continue de surveiller l'innocuité des produits de santé pour identifier et évaluer les dangers potentiels.
                            Cette surveillance comprend l'analyse de diverses sources d'information (déclarations d'effets indésirables, nouvelles informations
                            sur l'innocuité provenant d'organismes de réglementation étrangers, littérature médicale et scientifique) pour identifier des
                            problèmes d'innocuité potentiels liés aux produits de santé.</p>
                        <!--h3-section-start-->
                        <section>
                            <h3 id="a4.1">Paramètres</h3>
                            <p>Il y a trois paramètres dans la requête: id, lang et type.</p>
                            <table>
                                <caption>
                                    Paramètres pour la requête
                                </caption>
                                <tr>
                                    <th scope="col">Paramètre</th>
                                    <th scope="col">Définition</th>
                                    <th scope="col">Valeur</th>
                                    <th scope="col">Requis?</th>
                                    <th scope="col">Note</th>
                                </tr>
                                <tr>
                                    <td><span class="nowrap">regcontent/api/safetyreview?id=SSR00001</span></td>
                                    <td>Affiche l'examen de l'innocuité selon le format du rapport spécifié dans la requête.</td>
                                    <td>
                                        <ul class="list-unstyled mrgn-lft-0 wrap">
                                            #####&nbsp;- format du rapport
                                        </ul>
                                    </td>
                                    <td><strong>Oui</strong></td>
                                    <td></td>
                                </tr>
                                <tr>
                                    <td><span class="nowrap">regcontent/api/safetyreview/?lang=fr</span></td>
                                    <td>Modifie la langue du résultat affiché.</td>
                                    <td>
                                        <ul class="list-unstyled mrgn-lft-0 nowrap">
                                            <li><code>en</code>&nbsp;- Anglais</li>
                                            <li><code>fr</code>&nbsp;- Fran&ccedil;ais</li>
                                        </ul>
                                    </td>
                                    <td><strong>Non</strong>, mais l'anglais est la langue par défaut si elle n'est pas spécifiée</td>
                                    <td>Détermine si le résultat est affiché en anglais ou en français.</td>
                                </tr>
                                <tr>
                                    <td><span class="nowrap">regcontent/api/safetyreview/?type=json</span></td>
                                    <td>Modifie le format du résultat.</td>
                                    <td>
                                        <ul class="list-unstyled mrgn-lft-0 nowrap">
                                            <li><code>json</code>&nbsp;- JSON</li>
                                            <li><code>xml</code>&nbsp;- XML</li>
                                            <li><code>csv</code>&nbsp;- CSV</li>
                                        </ul>
                                    </td>
                                    <td><strong>Non</strong>, mais JSON est le format par défaut s'il n'est pas spécifié.</td>
                                    <td>Détermine si le résultat est en format JSON, XML ou CSV.</td>
                                </tr>
                            </table>
                            <p>La liste des Summary safety reviews peut être accédée aux adresses URI suivantes&nbsp;:</p>
                            <ul>
                                <li><a href="https://imsd.hres.ca/regcontent/api/safetyreview/?lang=en&type=json">https://imsd.hres.ca/regcontent/api/safetyreview/?lang=en&type=json</a></li>
                                <li><a href="https://imsd.hres.ca/regcontent/api/safetyreview/?lang=fr&type=json">https://imsd.hres.ca/regcontent/api/safetyreview/?lang=fr&type=json</a></li>
                            </ul>
                        </section>                        
                        <section>
                            <h3 id="a4.2">Format du résultat</h3>
                            <p>Le <strong>résultat</strong> contient un ou plusieurs objets.</p>
                            <p>Chaque objet &nbsp;<strong>summary safety reviews</strong>&nbsp;contient les valeurs suivantes&nbsp;:</p>
                            <table>
                                <caption>
                                    Valeurs de l'objet Summary safety reviews
                                </caption>
                                <tr>
                                    <th scope="col">Code</th>
                                    <th scope="col">Valeur</th>
                                </tr>
                                <tr>
                                    <td><strong>template</strong></td>
                                    <td>There are two different formats for the SSRs.  This variable defines which template is used.  Possible values are 1 or 2.</td>
                                </tr>
                                <tr>
                                    <td><strong>link_id</strong></td>
                                    <td>This variable is used to link all of the SSR data together.</td>
                                </tr>
                                <!--

                                <tr>
                                    <td><strong>review_date </strong></td>
                                    <td>Unused data element ????.</td>
                                </tr>

                                -->

                                <tr>
                                    <td><strong>drug_name </strong></td>
                                    <td>The name of the drug, Class, or active ingredient.</td>
                                </tr>
                                <tr>
                                    <td><strong>safety_issue</strong></td>
                                    <td>The safety issue text (in template #2).</td>
                                </tr>
                                <tr>
                                    <td><strong>issue</strong></td>
                                    <td>The safety issue text (in template #1).</td>
                                </tr>
                                <tr>
                                    <td><strong>background</strong></td>
                                    <td>The background information text (in template #1).</td>
                                </tr>
                                <tr>
                                    <td><strong>objective</strong></td>
                                    <td>The objective text (in template #1).</td>
                                </tr>
                                <tr>
                                    <td><strong>key_findings</strong></td>
                                    <td>A reference number to the text for the key findings (in template #1).</td>
                                </tr>
                                <tr>
                                    <td><strong>key_messages</strong></td>
                                    <td>A reference number to the text for the key messages (in template #2).</td>
                                </tr>
                                <tr>
                                    <td><strong>overview</strong></td>
                                    <td>The overview text (in template #2).</td>
                                </tr>
                                <tr>
                                    <td><strong>use_canada</strong></td>
                                    <td>A reference number to the text for the Use in Canada (in template #2).</td>
                                </tr>
                                <tr>
                                    <td><strong>findings</strong></td>
                                    <td>The Safety Review Findings (in template #2).</td>
                                </tr>
                                <tr>
                                    <td><strong>conclusion</strong></td>
                                    <td>A reference number to the text for Conclusions and Actions.</td>
                                </tr>
                                <tr>
                                    <td><strong>additional</strong></td>
                                    <td>The Additional Information text.</td>
                                </tr>
                                <tr>
                                    <td><strong>full_review</strong></td>
                                    <td>The Full review reports text.</td>
                                </tr>
                                <tr>
                                    <td><strong>references</strong></td>
                                    <td>A reference number to the text for the References list.</td>
                                </tr>
                                <tr>
                                    <td><strong>footnotes</strong></td>
                                    <td>A reference number to the text for the Footnotes list.</td>
                                </tr>
                                <tr>
                                    <td><strong>created_date</strong></td>
                                    <td>The date the SSR was created.</td>
                                </tr>
                                <tr>
                                    <td><strong>num_order</strong></td>
                                    <td>The ordering number for the bulleted lists.</td>
                                </tr>
                                <tr>
                                    <td><strong>field_id_en</strong></td>
                                    <td>The reference number linked to from the main table.</td>
                                </tr>
                                <tr>
                                    <td><strong>bullet_value_en</strong></td>
                                    <td>The text of the bullet points in English.</td>
                                </tr>
                                <tr>
                                    <td><strong>field_id_fr</strong></td>
                                    <td>The reference number linked to from the main table.</td>
                                </tr>
                                <tr>
                                    <td><strong>bullet_view_fr</strong></td>
                                    <td>The text of the bullet points in French.</td>
                                </tr>

                                <!--
                                <tr>
                                    <td><strong>modified_date</strong></td>
                                    <td>The date the page was modified. ????? yellow comment</td>
                                </tr>                                -->
                                                    <!--<tr>
                                    <td><strong>key_message_list</strong></td>
                                    <td>The product key message list.</td>
                                </tr>
                                <tr>
                                    <td><strong>footnotes_list</strong></td>
                                    <td>The product footnotes list.</td>
                                </tr>
                                <tr>
                                    <td><strong>reference_list</strong></td>
                                    <td>The product reference list.</td>
                                </tr>
                                <tr>
                                    <td><strong>use_canada_list</strong></td>
                                    <td>The list of?????.</td>
                                </tr>
                                <tr>
                                    <td><strong>finding_list</strong></td>
                                    <td>The product finding list.</td>
                                </tr>
                                <tr>
                                    <td><strong>conclusion_list</strong></td>
                                    <td>The product conclusion list.</td>
                                </tr>-->
                            </table>
                        </section>
                        <section>
                             <h3 id="a4.3">Exemple de résultat</h3>
                             <pre class="prettify prettyprint linenums">{"Template":2,"LinkId":"SSR00001","ReviewDate":null,"DrugName":"Galexos (simeprevir)","Safetyissue":"Severe liver problems","Issue":"","Background":"","Objective":"","KeyFindings":"","KeyMessages":1,"Overview":"Health Canada carried out a safety review after Japan published a risk communication on severe liver problems and related death with the use of simeprevir. In patients with liver damage due to advanced chronic hepatitis C, increased levels of bilirubin in the blood can be a sign that the liver is not functioning properly. The use of simeprevir can further increase bilirubin levels in the blood; this risk is already included in the prescribing information.","UseCanada":2,"Findings":3,"Conclusion":4,"Additional":"<p>The analysis that contributed to this safety review included scientific and medical literature, Canadian and international adverse reaction reports and what is known about the use of this drug both in Canada and internationally.</p><p>For additional information, <a href=\"http://www.hc-sc.gc.ca/contact/dhp-mps/hpfb-dgpsa/mhp-psc-eng.php\">contact the Marketed Health Products Directorate</a>.<u> </u></p>","FullReview":"","References":0,"Footnotes":0,"CreatedDate":"2016-01-27","ModifiedDate":"2016-01-27","KeyMessageList":[{"FieldId":1,"OrderNo":1,"Bullet":"Galexos (simeprevir) is a drug used to treat chronic hepatitis C."},{"FieldId":1,"OrderNo":2,"Bullet":"A safety review was carried out by Health Canada after Japan published a risk communication on severe liver problems and related death with simeprevir use."},{"FieldId":1,"OrderNo":3,"Bullet":"The prescribing information for Galexos has been updated with warnings about the risk of severe liver problems and related death. It also reminds healthcare professionals to frequently monitor patients for liver problems when using this drug."}],"FootnotesList":[],"ReferenceList":[],"UseCanadaList":[{"FieldId":2,"OrderNo":1,"Bullet":"Simeprevir has been marketed in Canada under the brand name of Galexos since 2013."},{"FieldId":2,"OrderNo":2,"Bullet":"Simeprevir is a drug used for the treatment of chronic hepatitis C. It is taken as an oral tablet for 12 weeks in combination with other medicinal products such as peginterferon alfa and ribavirin or with sofosbuvir."},{"FieldId":2,"OrderNo":3,"Bullet":"Recently, the number of prescriptions in Canada for simeprevir has gone from 1700 prescriptions between July and September 2014, to 16 prescriptions between July and September 2015."}],"FindingList":[{"FieldId":3,"OrderNo":1,"Bullet":"At the time of the review, Health Canada had received 11 Canadian reports of severe liver problems, including 2 deaths, suspected of being linked with simeprevir. Upon review of these cases, no conclusions could be made regarding what role, if any, the drug may have played, due to limited information from these cases."},{"FieldId":3,"OrderNo":2,"Bullet":"In Japan, 8 cases of severe blood bilirubin levels and 3 deaths had been reported in association with simeprevir. Ethnic differences in susceptibility to liver problems exist, therefore the information from these cases needs to be interpreted with caution when considering the risk of simeprevir for other populations."},{"FieldId":3,"OrderNo":3,"Bullet":"Information was also received from the manufacturer about cases of severely abnormal bilirubin levels suspected of being linked with simeprevir. In some of these cases, the contribution of simeprivir to the side effect could not be ruled out."}],"ConclusionList":[{"FieldId":4,"OrderNo":1,"Bullet":"Based on all the information reviewed, Health Canada concluded that the prescribing information should be updated to reflect the level of evidence related to the risk of severe liver problems."},{"FieldId":4,"OrderNo":2,"Bullet":"The manufacturer of Galexos (simeprevir) has updated the prescribing information to: <ul><li>Warn about the risk of severe liver problems and related death,</li><li>Advise healthcare professionals to do blood tests to check for liver function before and during treatment, and</li><li>Not use Galexos (simeprevir) in patients who have moderate or severe liver damage.</li></ul>"},{"FieldId":4,"OrderNo":3,"Bullet":"Health Canada will publish a labelling update notice in the January 2016 issue of the Health Product InfoWatch to raise awareness of the labelling update for simeprevir."},{"FieldId":4,"OrderNo":4,"Bullet":"Health Canada will continue to monitor side effect information involving simeprevir, as it does for all health products on the Canadian market, to identify and assess potential harms. Health Canada will take appropriate and timely action if and when any new health risks are identified."}]}</pre>
                        </section>                            
                        <section>
                             <h3 id="a4.4">Exemple de jQuery</h3>
                             <p>Exemple d'une fonctionnalité qui recherche un examen de l'innocuité selon le format d'un rapport et la langue sélectionnée&nbsp;:</p>
                             <pre class="prettify prettyprint linenums">function getSummarySafetyReview(id, lang) {
     var base = 'https://imsd.hres.ca';
     var uri = base + '/regcontent/api/safetyreview/?lang=' + lang + '&id=' + id;
     $.ajax({
              url:uri,
              type:'GET',
              Accept:&quot;application/json&quot;,
              dataType: 'json',
              success:function(data){
                           console.log(data.drug_name);
                           var frag = document.createDocumentFragment();
                           var h2 = document.createElement(&quot;h2&quot;);
                           var DrugName = document.createTextNode(data.drug_name);
                           var p = document.createElement(&quot;p&quot;);
                           var text = document.createTextNode(data.panels[0].text);
                           h2.appendChild(Brandname);
                           p.appendChild(text);
                           frag.appendChild(h2);
                           frag.appendChild(p);
                           $(&quot;#responses&quot;)[0].appendChild(frag);
               },
               error:function(error){
               },
     });
     return;
 };			</pre>    
                        </section>
                    </section><!--Summary Safety Review-section-start-->
                </section><!--END Entire Doc Section-->
            </div>
            <!-- prefooter-en.html-Start-->
            <div id="def-preFooter">
                <link rel="import" href="./StaticFallbackFiles/gcweb/prefooter-fr.html">
            </div>
            <!-- prefooter-en.html-End-->
            <!-- Write closure template -->
            <script type="text/javascript">
                var defPreFooter = document.getElementById("def-preFooter");
                defPreFooter.outerHTML = wet.builder.preFooter({
                    cdnEnv: "prod",
                    dateModified: "2017-06-27",
                    showPostContent: true,
                    showShare: true,
                });
            </script>
        </main>
    </div>

    <!-- footer-en.html-Start-->
    <div id="def-footer">
        <link rel="import" href="./StaticFallbackFiles/gcweb/footer-fr.html">
    </div>
    <!-- footer-en.html-End-->
    <!-- Write closure template -->
    <script type="text/javascript">
            var defFooter = document.getElementById("def-footer");
            defFooter.outerHTML = wet.builder.footer({
                cdnEnv: "prod",
                showFeatures: true,
            });
    </script>
    <!-- Write closure template -->
    <script type="text/javascript">
                document.write(wet.builder.refFooter({
                    cdnEnv: "prod"
                }));
    </script>
    <!--[if lt IE 10 | !IE ]><!-->
    <script src="./js/jquery.xdomainrequest.min.js"></script>
    <!--<![endif]-->
</body>
</html>